Why the study?
Does a Japan-specific rivaroxaban dose demonstrate safety compared to warfarin in Japanese patients with atrial fibrillation?
Does a Japan-specific rivaroxaban dose demonstrate safety compared to warfarin in Japanese patients with atrial fibrillation?
A Japan-specific dose of rivaroxaban is safe in Japanese patients with atrial fibrillation, supporting the applicability of global ROCKET AF results to this population.
May inform Japan-specific rivaroxaban dosing in AF; leaves open broader confirmation of global ROCKET AF applicability.
J-ROCKET AF demonstrated the safety of a Japan-specific rivaroxaban dose and supports bridging the global ROCKET AF results into Japanese clinical practice.
No takes yet. Share an insight, caveat, or question.
Hori et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: